Phase 1 Trial

Adagene Inc (NASDAQ: ADAG) announced clinical data on ADG116, and ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021. ADG116 monotherapy in Phase 1 study was well-tolerated up to 6 mg/kg with only mild or moderate...

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exercise price of $1.69 per share. Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) also ...

Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors. IMC-C103C was developed using the Company's ImmTAC technology platform and is being developed in partnership...

Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma.  Adicet's AD-001 is an off-the-shelf cell therapy developed by engineering a CD20-targeting chimeric antigen...

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. The Company also shared new preclinical...

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker...

Molecular Partners AG (NASDAQ: MOLN) announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference. The...

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Human Papillomavirus positive (HPV16+) solid tumors.  The investigational cell therapy is being evaluated in certain patients with...

The FDA has granted Orphan Drug designation to Inhibrx Inc's (NASDAQ: INBX) INBRX-109 for chondrosarcoma. Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the U.S. and the European Union.  Currently, there are no...

Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ: MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clinical development in COVID-19.  Analyst Jonathan Aschoff expects...

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. Arbutus shares are soaring after...

Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with Bristol Myers Squibb Co (NYSE: BMY) Opdivo (nivolumab) in select recurrent advanced/metastatic solid tumors. As of the...

Olema Pharmaceuticals Inc (NASDAQ: OLMA) had been preparing to present the first clinical data from its lead program in development for metastatic breast cancer at a conference next week. But its poster supposedly leaked online on Monday.  In response, Olema issued a statement...

Hoth Therapeutics Inc (NASDAQ: HOTH) has begun enrollment and dosing for the second cohort in its Phase 1b trial of topical BioLexa to treat mild to moderate atopic dermatitis, also known as eczema.  What happened: The Company is conducting the trial in Australia, which includes mild...